Tandem Diabetes (TNDM) Tops Q2 EPS by 6c

Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $15.7 million versus the consensus estimate of $14.92 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight
• Seaport Global Securities Upgrades Asbury Automotive Group (ABG) to Buy